In addition, these findings indicate that the molecular ‘rewiring’ of tumor cells after acquired resistance to PD-L1 requires the complex molecular and cellular changes from host processes that indirectly alter tumor cell PD-L1 and IFN signaling. The gene discussed is CD274; the disease is neoplasm.